Decoy Therapeutics Inc.(DCOY)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .

Decoy Therapeutics Inc. (DCOY) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. DCOY is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $5.2m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Decoy Therapeutics Inc. reports quarterly revenue of $227.6K, net income of $-2.4M. Top institutional holders of DCOY by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, Tower Research Capital (TRC), UBS Group AG, based on the most recent SEC filings. DCOY trades on the Nasdaq exchange and files with the SEC under CIK 1615219. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DCOY daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Decoy Therapeutics Inc. directly from SEC EDGAR.

Revenue

$227.6K

Net Income

$-2.4M

DCOY key financials by period

Decoy Therapeutics Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodFormRevenueNet incomeOperating margin
FY 202110-K$1.8M$-12.8M—
FY 202010-K$5.2M$-7.4M-148.8%
FY 201910-K$3.5M$-6.9M—
FY 201810-K$2.0M$-1.7M-86.3%
FY 201710-K$1.3M$-34.4M—
FY 201610-K$1.0M$-39.5M—

Institutions holding DCOY

Institutional investors reporting a position in Decoy Therapeutics Inc. on SEC Form 13F.
InstitutionSharesValueReported
VANGUARD CAPITAL MANAGEMENT4,034$29.0K2026-06-30
Tower Research Capital (TRC)256$1.8K2026-06-30
UBS Group AG25$180.002026-06-30
Caitong International Asset Management , Ltd2$14.002026-06-30
SEC EDGAR: CIK 1615219 →
DCOY

Decoy Therapeutics Inc.

DCOY
NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $5.2M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Price Chart

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.
Reading the latest SEC filing… (first load can take ~20s)

Key Metrics

Revenue

Q2 2026
EDGAR

$227.6K

Net Income

Q2 2026
EDGAR

$-2.37M

EPS (Diluted)

Q2 2026
EDGAR

$-4.46

Top Institutional Holders

as of Q2 2026
$31.0K total
VANGUARD CAPITAL MANAGEMENT LLC
$29.0KNew
Tower Research Capital LLC (TRC)
$1.8K-74.9%
UBS Group AG
$180-95.4%
Caitong International Asset Management Co., Ltd
$14New

Financial Trends

Revenue & Net Income

Earnings Per Share

Loading ratio trend…